Next 10 |
home / stock / acrs / acrs articles
The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on de...
BioCryst Pharmaceuticals (NASDAQ: BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. T...
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern aro...
HC Wainwright has downgraded Aclaris Therapeutics Inc (NASDAQ:ACRS). Earlier this month, the company released topline results from its Ph...
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded...
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreemen...
Aclaris Therapeutics Inc (NASDAQ:ACRS) has announced leadership changes as the company undertakes a strategic review of its business. Aclaris and...
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topic...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...